Ep. 336 Biomarkers in Treatment Intensification for Prostate Cancer with Dr. Angela Jia

0:00-47:40

Same risk group, very different benefit. Can biomarkers help identify who needs treatment intensification in prostate cancer? On this episode of BackTable Urology, Dr. Ruchika Talwar and Dr. Angela Jia, a radiation oncologist at University Hospitals Cleveland Medical Center, break down the difference between prognostic and predictive biomarkers and how genomic testing is informing the way clinicians counsel patients. They review trial data suggesting that men with a low genomic score may gain little from adding hormone therapy, along with early prospective evidence that the luminal B subtype may help identify who benefits most from intensification. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Verasyte https://www.veracyte.com/ --- Timestamps 00:00 - Introduction 02:08 - Prognostic vs. Predictive Biomarkers 06:34 - The NRG/RTOG 0815 Biomarker Cohort 10:15 - Applying a Low Genomic Score in Clinic 15:16 - Genomic Classifiers After Prostatectomy 18:52 - RTOG 9601, SPPORT and the Salvage Evidence 24:39 - Stage Migration and the Case for an ARPI 28:13 - Ordering and Reading the Genomic Report 34:31 - Common Mistakes in Interpretation 37:31 - Where Genomics Could Go Next 41:03 - Reflex Testing, EMR Integration and AI 44:44 - Closing Remarks --- More about this episode The conversation covers practical application of test results, counseling with absolute risk numbers, and the pitfalls of stretching predictive claims beyond their evidence.

Publisher

BackTable Urology

Published

October 15, 2026

Duration

48 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

BackTable Inc.

BU

BackTable Urology

@backtableurology

#treatmentintensification #prostatecancer #angelajia #medicine

The Nile